- If you are wondering whether QuidelOrtho's current share price reflects its underlying value, this article walks through the key numbers that investors tend to focus on before making a decision.
- QuidelOrtho last closed at US$15.88, with returns of 4.1% over the past week, a 23.8% decline over the past month, and year to date and 1 year returns of 44.8% and 44.0% declines respectively. The 3 year and 5 year returns sit at 82.5% and 87.5% declines.
- These moves come as investors reassess the company against its peers and its long term prospects, with sentiment feeding directly into how much risk the market is willing to price in. That context is important, because large price swings can matter a lot when you are trying to judge whether the current valuation still makes sense.
- On Simply Wall St's 6 point valuation checklist, QuidelOrtho currently scores 5 out of 6, which sets the stage for a closer look at how different valuation approaches line up and hints at an even more complete way to think about value that will be covered at the end of this article.
Find out why QuidelOrtho's -44.0% return over the last year is lagging behind its peers.
Approach 1: QuidelOrtho Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today’s dollars, aiming to show what those future streams might be worth right now.
For QuidelOrtho, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at a loss of $84.9 million. Analysts supply explicit forecasts through 2029, including projected free cash flow of $544 million in 2029, with further years estimated by Simply Wall St to gradually increase out to 2035. All cash flows here are in $ and, based on the data, remain in the hundreds of millions rather than crossing into the billions.
When these projected cash flows are discounted back, the model arrives at an estimated intrinsic value of US$80.65 per share. Against the recent share price of US$15.88, this implies the stock is 80.3% undervalued according to this DCF output.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests QuidelOrtho is undervalued by 80.3%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.
Approach 2: QuidelOrtho Price vs Sales
For companies where earnings are weak or volatile, the P/S ratio is often a more useful yardstick because it focuses on revenue rather than profit swings that can be affected by one off items or accounting choices.
What investors are really weighing up is how much they are paying for each dollar of sales, given the company’s growth outlook and risk profile. Higher expected growth or lower perceived risk can justify a higher “normal” P/S multiple, while slower growth or higher risk usually points to a lower one.
QuidelOrtho currently trades on a P/S of 0.40x. That is well below the Medical Equipment industry average P/S of 2.60x and also below the peer group average of 1.56x. Simply Wall St’s Fair Ratio for QuidelOrtho is 1.08x, which is its proprietary view of what the P/S should be after considering factors such as earnings growth, profit margins, industry, market cap and stock specific risks.
This Fair Ratio framework can be more informative than a simple comparison with peers or the industry because it adjusts for company specific characteristics rather than assuming all businesses deserve the same multiple.
With the current 0.40x P/S below the 1.08x Fair Ratio, the shares appear undervalued on this metric.
Result: UNDERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your QuidelOrtho Narrative
Earlier the article mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple story behind the numbers by linking your view on QuidelOrtho's future revenue, earnings and margins to a financial forecast and then to a fair value that you can compare with the current share price to decide whether the gap between price and value suits your own investment timing.
On Simply Wall St's Community page, Narratives sit inside an easy tool used by many investors, where you can see and edit assumptions instead of just accepting a single target. The fair value also updates automatically when new information such as earnings or news is added to the model.
For QuidelOrtho, one Narrative might line up with the higher analyst price target of US$50.00 and build a story around faster margin improvement and stronger demand. Another might align with the lower analyst view at US$22.00 and focus on reimbursement pressure or competition. By comparing these side by side you can decide which story feels more realistic and adjust the inputs to create your own version.
Do you think there's more to the story for QuidelOrtho? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com